Table 1. Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.
| Patient Characteristics | Severity of Liver Disease | p-value | |
|---|---|---|---|
| Mild N. Patients: 86 (%) | Moderate-to-Severe N. Patients: 363 (%) | ||
| Median age | 64 years (range: 29–82) | 65 years (range: 45–82) | 0.7 |
| Gender: male/female | 38/48 (44/54) | 217/145 (60/40) | <0.01 |
| Genotype Distribution | |||
| 1a | 9 (11) | 48 (13) | 0.6 |
| 1b | 46 (53) | 186 (51) | 0.7 |
| 2 | 17 (20) | 52 (14) | 0.2 |
| 3 | 7 (8) | 55 (15) | 0.1 |
| 4 | 7 (8) | 22 (6) | 0.5 |
| Comedications | |||
| 1 drug | 34 (40) | 100 (28) | 0.03 |
| 2 drugs | 18 (21) | 81 (22) | 0.9 |
| 3 drugs | 15 (17) | 65 (18) | 1 |
| 4 drugs | 10 (12) | 55 (15) | 0.4 |
| 5 drugs | 5 (6) | 32 (9) | 0.5 |
| >5 drugs (range 6–12) | 4 (5) | 33 (9) | 0.2 |
| DAA regimens | |||
| Sofosbuvir+Ribavirin | 28 (33) | 105 (29) | 0.5 |
| Sofosbuvir+Simeprevir | 20 (23) | 95 (26) | 0.7 |
| Sofosbuvir+Daclatasvir | 6 (7) | 40 (11) | 0.3 |
| Sofosbuvir+Ledipasvir | 9 (10) | 44 (12) | 0.8 |
| Paritaprevir/ritonavir, ombitasvir, dasabuvir | 23 (27) | 78 (21) | 0.3 |